Hormone and antihormone withdrawal: Implications for the management of androgen-independent prostate cancer

Urology

Volumn 47, Issue 1 SUPPL. 1, 1996, Pages 61-69

  Scher, Howard I ^a,b,c   Zhang, Zuo Feng ^b,c   Nanus, David ^c   Kelly, William Kevin ^a,c  

^a Gastrointestinal Oncology Solid Tumor Service   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANGIOPEPTIN; ANTIANDROGEN; BICALUTAMIDE; BROMOCRIPTINE; DIETHYLSTILBESTROL; ESTROGEN; FLUTAMIDE; GESTAGEN; GONADORELIN DERIVATIVE; HYDROCORTISONE; KETOCONAZOLE; MEGESTROL ACETATE; PROSTATE SPECIFIC ANTIGEN; STEROID RECEPTOR; SURAMIN;

ADULT; AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CASTRATION; CONFERENCE PAPER; DRUG MECHANISM; DRUG WITHDRAWAL; HORMONE RECEPTOR INTERACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CARCINOMA; RECURRENT CANCER;

AMINOGLUTETHIMIDE; ANDROGEN ANTAGONISTS; CLINICAL TRIALS; FLUTAMIDE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0029619536     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0090-4295(96)80011-2     Document Type: Article

References (18)

1. Wilding G, Chen M, and Gelmann EP: Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 14: 103-114, 1989.
2. Veldscholte J, Ris-Stalpers C, Kuiper GGJM, Jenster G, Berrevoets C, Claassen E, van Rooij HCJ, Trapman J, Brinkmann AO, and Mulder E: A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173: 534-543, 1990.
3. Veldscholte J, Berrevoets CA, Ris Stalpers C, Kuiper GG, Jenster G, Trapman J, Brinkmann AO, and Mulder E: The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 41: 665-669, 1992.
4. Kelly WK, and Scher HI: Prostate specific antigen decline after antiandrogen withdrawal. J Urol 149: 607-609, 1993.
5. Scher HI, and Kelly WK: The flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostatic cancer. J Clin Oncol 11: 1566-1572, 1993.
6. Dupont A, Gomez J, Cusan L, Koutsilieris M, and Labrie F: Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 150: 908-913, 1993.
7. Sartor O, Cooper M, Weinberger M, Headlee D, Tompkins A, Thibault A, and Myers CE: Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer. J Natl Cancer Inst 86: 222-227, 1994.
8. Small EJ, and Carroll PR: Prostate-specific antigen decline after bicalutamide withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 43: 408-410, 1994.
9. Nieh PT: Withdrawal phenomenon with the antiandrogen bicalutamide. J Urol 153: 1070-1073, 1995.
10. Schuurmans ALG, Bolt J, Voorhorst M, Blankenstein MA, and Mulder E: Regulation of growth and epidermal growth factor receptor levels of LNCaP prostate tumor cells by different steroids. Int J Cancer 42: 917-922, 1988.
11. 3") prostate cancer: refining the concept. Urology 46: 142-148, 1995.
12. Cox DR Partial likelihood. Biometrika 62: 269-279, 1975.
13. Cox DR: Regression models and life table (with discussion). J R Stat Soc B34: 187-220, 1972.
14. Scher HI, Zhang Z-F, Cohen L, and Kelly WK Hormonally relapsed prostatic cancer: lessons from the flutamide withdrawal syndrome. Adv Urol 8: 61-95, 1995.
15. Slack NH, Murphy GP, and Participants in the National Prostatic Cancer Project: Criteria for evaluating patient responses to treatment modalities for prostatic cancer. Urol Clin North Am 11: 337, 1984.
16. Cusan L, Gomez J-L, Dupont A, Diamond P, Lemay M, Moore S, and Labrie F: Metastatic prostate cancer pulmonary nodules: beneficial effects of combination therapy and subsequent withdrawal of flutamide. Prostate 24: 257-261, 1994.
17. Herrada J, Hossan B, Amato R, Zukiwski A, von Eschenbach A, and Logothetis C: Adrenal androgens predict for early progression to flutamide withdrawal in patients (PTS) with androgen independent prostate carcinoma (AlPCa). Proc Am Soc Clin Oncol 13: 237, 1994.
18. 2 prostate cancer. Am J Med 98: 412-414, 1995.